Eris Lifesciences Bilan de santé
Santé financière contrôle des critères 3/6
Eris Lifesciences possède un total de capitaux propres de ₹31.8B et une dette totale de ₹27.0B, ce qui porte son ratio d'endettement à 84.8%. Son actif total et son passif total sont ₹70.2B et de ₹38.4B. L'EBIT de Eris Lifesciences est ₹5.8B ce qui fait que son ratio de couverture des intérêts 3.6. Elle dispose de liquidités et de placements à court terme de ₹2.4B.
Informations clés
84.8%
Ratio d'endettement
₹26.95b
Dette
| Ratio de couverture des intérêts | 3.6x |
| Argent liquide | ₹2.43b |
| Fonds propres | ₹31.77b |
| Total du passif | ₹38.45b |
| Total des actifs | ₹70.22b |
Mises à jour récentes de la santé financière
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Recent updates
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Analyse de la situation financière
Passif à court terme: Les actifs à court terme de ERIS ( ₹13.2B ) dépassent ses passifs à court terme ( ₹12.3B ).
Passif à long terme: Les actifs à court terme de ERIS ( ₹13.2B ) ne couvrent pas ses passifs à long terme ( ₹26.1B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de ERIS ( 77.2% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de ERIS est passé de 1% à 84.8% au cours des 5 dernières années.
Couverture de la dette: La dette de ERIS est bien couverte par le flux de trésorerie opérationnel ( 26.2% ).
Couverture des intérêts: Les paiements d'intérêts de ERIS sur sa dette sont bien couverts par l'EBIT ( 3.6 x couverture).